Stock 9926 AKESO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Akeso, Inc.

Equities

9926

KYG0146B1032

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:13 2024-07-03 am EDT 		5-day change 1st Jan Change
37.8 HKD +1.75% Intraday chart for Akeso, Inc. -1.18% -18.53%
Jul. 01 Akeso, Inc. Announces Change of Directors CI
Jun. 04 Akeso Expands Territory of License Agreement for Lung Cancer Drug MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Akeso, Inc. Announces Change of Directors
CI
Akeso Expands Territory of License Agreement for Lung Cancer Drug
MT
Summit Therapeutics Inc. Expands License Territories for Ivonescimab
CI
Akeso's Phase 3 Trial for Non-Small Cell Lung Cancer Treatment Meets Primary Endpoint; Shares Rise 15%
MT
Akeso, Inc. Announces Registration Phase III Clinical Trial, AK112-303 (HARMONi-2) of ivonescimab (AK112, PD-1/VEGF)
CI
Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival
CI
Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut
MT
Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20%
MT
Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection
CI
Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator
MT
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer
CI
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
AQ
Akeso to Raise Over HK$1 Billion Via Share Sale
MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast
MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC
CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5%
MT
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023
CI
Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy
MT
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9926 Stock
  4. News Akeso, Inc.